Spyre Therapeutics, Inc.
86.93USD
-3.8600 (-4.25%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 0 | 0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -42 | -46 | -57 | -57 | -42 | -54 | -61 | -55 |
| Net Income | -36 | -69 | -63 | -11 | -37 | -45 | -56 | -69 |
| EPS (Diluted) | $-0.35 | $-0.74 | — | $-0.15 | — | — | — | $1.06 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)